PCS
PRLD icon

Personal CFO Solutions’s Prelude Therapeutics PRLD Stock Holding History

Personal CFO Solutions’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,500
Closed -$322K – 442
2020
Q4 		$322K Buy
+4,500
New +$224K 0.08% 230

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Personal CFO Solutions's PRLD Position: Q1 2021 in Review

Personal CFO Solutions sold out of Prelude Therapeutics (PRLD) in Q1 2021, closing a stake of 4,500 shares — an estimated $322K sold.

Personal CFO Solutions first reported a position in PRLD in Q4 2020 and held it in 1 quarter. The position peaked at $322K in Q4 2020. 60 funds tracked by Wall St. Rank hold PRLD as of Q1 2021.

  • Personal CFO Solutions reported no remaining Prelude Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Personal CFO Solutions sold 4,500 Prelude Therapeutics shares in Q1 2021, an estimated $322K.
  • Personal CFO Solutions first reported a position in Prelude Therapeutics in Q4 2020 and held it in 1 quarter.
  • Personal CFO Solutions's Prelude Therapeutics position peaked at $322K in Q4 2020.
  • 60 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2021.

Based on Personal CFO Solutions's 13F filing for Q1 2021, filed 21 Apr 2021.